These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34328574)

  • 1. Comparative study of a novel selective urate reabsorption inhibitor "dotinurad" among patient groups with different stages of renal dysfunction.
    Takahashi T; Beppu T; Hidaka Y; Hosoya T
    Clin Exp Nephrol; 2021 Dec; 25(12):1336-1345. PubMed ID: 34328574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study.
    Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):44-52. PubMed ID: 31754882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study.
    Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):53-61. PubMed ID: 31792640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout.
    Hosoya T; Furuno K; Kanda S
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):71-79. PubMed ID: 31970593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinical pharmacology study of the novel, selective urate reabsorption inhibitor dotinurad in outpatients.
    Hosoya T; Furuno K; Kanda S
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):103-111. PubMed ID: 32067130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor.
    Fukase H; Okui D; Sasaki T; Fushimi M; Ohashi T; Hosoya T
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):17-24. PubMed ID: 31823130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials.
    Takahashi T; Beppu T; Hidaka Y; Hosoya T
    Clin Exp Hypertens; 2021 Nov; 43(8):730-741. PubMed ID: 34425059
    [No Abstract]   [Full Text] [Related]  

  • 8. Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
    Kuriyama S
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):1-5. PubMed ID: 31754883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout.
    Ishikawa T; Takahashi T; Taniguchi T; Hosoya T
    Expert Opin Pharmacother; 2021 Aug; 22(11):1397-1406. PubMed ID: 33926357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor.
    Okui D; Sasaki T; Fushimi M; Ohashi T
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):92-102. PubMed ID: 31734820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout.
    Hosoya T; Fushimi M; Okui D; Sasaki T; Ohashi T
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):80-91. PubMed ID: 31875931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study.
    Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):62-70. PubMed ID: 31980978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of dotinurad in patients with severe renal dysfunction.
    Kurihara O; Yamada T; Kato K; Miyauchi Y
    Clin Exp Nephrol; 2024 Mar; 28(3):208-216. PubMed ID: 37864678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study.
    Osonoi T; Saito M; Hosoya M; Douguchi S; Ofuchi K; Katoh M
    Front Endocrinol (Lausanne); 2022; 13():1042061. PubMed ID: 36714585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Dotinurad on Serum Uric Acid Concentration in Chronic Kidney Disease Patients Treated with Febuxostat.
    Yamada T; Sakai Y; Kurihara O; Kashiwagi T; Iwabu M
    J Nippon Med Sch; 2024; 91(4):352-356. PubMed ID: 39231637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dotinurad restores exacerbated kidney dysfunction in hyperuricemic patients with chronic kidney disease.
    Amano H; Kobayashi S; Terawaki H
    BMC Nephrol; 2024 Mar; 25(1):97. PubMed ID: 38491453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Efficacy and Safety of Dotinurad on Uric Acid and Renal Function in Patients with Hyperuricemia and Advanced Chronic Kidney Disease: A Single Center, Retrospective Analysis.
    Yanai K; Hirai K; Kaneko S; Mutsuyoshi Y; Kitano T; Miyazawa H; Ito K; Ueda Y; Ookawara S; Morishita Y
    Drug Des Devel Ther; 2023; 17():3233-3248. PubMed ID: 37941891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA).
    Tanaka A; Taguchi I; Hisauchi I; Yoshida H; Shimabukuro M; Hongo H; Ishikawa T; Kadokami T; Yagi S; Sata M; Node K;
    Eur J Med Res; 2023 Jul; 28(1):238. PubMed ID: 37461063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment.
    Kumagai Y; Sakaki M; Furihata K; Ito T; Inoue K; Yoshida T; Matsumoto S; Furuno K; Hagino A
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):25-35. PubMed ID: 31760530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor.
    Taniguchi T; Ashizawa N; Matsumoto K; Saito R; Motoki K; Sakai M; Chikamatsu N; Hagihara C; Hashiba M; Iwanaga T
    J Pharmacol Exp Ther; 2019 Oct; 371(1):162-170. PubMed ID: 31371478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.